1. Home
  2. OCS

OCS

Oculis Holding AG Ordinary shares

Logo Oculis Holding AG Ordinary shares

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 3:16pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Founded: 2003 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 439.8M IPO Year: N/A
Target Price: $30.75 AVG Volume (30 days): 40.7K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.26 EPS Growth: N/A
52 Week Low/High: $9.00 - $14.50 Next Earning Date: 05-18-2024
Revenue: $1,051,190 Revenue Growth: 6.51%
Revenue Growth (this year): 4.64% Revenue Growth (next year): 176.73%

Share on Social Networks: